ArticleJournal for immunotherapy of cancer2019

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Marijo Bilusic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.